Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) is a homodimeric, bifunctional enzyme that catalyzes the final two steps of the de novo purine biosynthetic pathway. The C-terminal domain of ATIC possesses phosphoribosylaminoimidazolecarboxamide formyltransferase (AICAR transformylase) activity, which transfers a formyl group to AICAR to produce FAICAR, while the N-terminal domain exhibits IMP cyclohydrolase activity, cyclizing FAICAR to inosine monophosphate (IMP). Because rapidly proliferating cells rely heavily on de novo purine synthesis for DNA and RNA replication, ATIC is highly expressed in various cancers, including lung adenocarcinoma and hepatocellular carcinoma, making it an attractive oncology target. Additionally, genetic deficiency in ATIC leads to AICA-ribosiduria, a rare, neurologically devastating metabolic disorder characterized by the accumulation of AICAR (ZMP) and its excretion as AICA-riboside. Clinically, ATIC is targeted by antifolate chemotherapeutics and anti-inflammatory agents such as pemetrexed and methotrexate. Inhibition of ATIC leads to the accumulation of intracellular ZMP, an AMP analogue that allosterically activates AMP-activated protein kinase (AMPK), thereby suppressing mTOR signaling and contributing to the anti-proliferative and anti-inflammatory efficacy of these drugs.
Inhibition of the AICAR transformylase activity of ATIC, preventing the conversion of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR/ZMP) to formyl-AICAR (FAICAR). This leads to the accumulation of intracellular ZMP, which acts as an AMP mimetic to allosterically activate AMP-activated protein kinase (AMPK) and inhibit de novo purine synthesis, thereby suppressing cell proliferation and inflammatory pathways.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC).